2024 Partners

NATERA

Natera

Lead Partner

Natera™ has developed one of the largest known clinico-genomic database for renal disease. This database is built with matched data from 40,000 patients who have received the Renasight™ test, a 385-gene panel for patients with kidney disease. Natera’s™ database enables drug developers to accelerate pre-clinical target discovery, enroll clinical trials faster, and maximize budgets for approved targeted therapies.

www.natera.com/organ-health

george clinical

George Clinical

Hosting Partner

George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. George Clinical is known as the industry-leading CRO for our innovative leadership in the kidney space. With more than 20 years of experience and 500 people managing 39 geographical locations throughout the USA, Asia-Pacific region, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials

www.georgeclinical.com

nordic

Nordic Bioscience

Expertise Partner

Nordic Bioscience is a biotech company founded in 1992 located in Herlev, Denmark. Nordic Bioscience is focused on the development, testing and validation of new blood based biochemical markers for diagnosis and prognosis of fibrotic and inflammatory diseases. We are a science-driven company that invests heavily in developing blood-based precision medicine solutions for the pharmaceutical industry as well as for patient care through our research and development division. Our central laboratory division offers a complete portfolio of central laboratory services as well as novel biomarker measures.

www.nordicbioscience.com

seastarr-image

SeaStar Medical

Expertise Partner

SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of a dysregulated immune response on vital organs. SeaStar Medical’s novel selective cytopheretic device (SCD) is designed to provide a potentially life-saving solution to critically ill patients. The SCD is a cell-directed extracorporeal therapy that targets the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. Promising data from multiple studies show that the SCD has the potential to improve clinical outcomes including overall survival and dialysis independence in acute kidney injury.

www.seastarmedical.com

Antaros Medical

Antaros Medical

Program Partner

Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.

www.antarosmedical.com

newcells

Newcells Biotech

Innovation Partner

Newcells Biotech provides clients with validated in vitro tools to understand how drugs interact with tissues. We build functional in vitro models of the kidney, retina and lung to improve clinical translation and drug discovery. By applying our expertise in induced pluripotent stem cells (iPSCs), primary tissues, a deep understanding of cellular physiology and organoid technology, we have built validated models and assays that have proven to be predictive of how drugs interact with tissues and organs.

www.newcellsbiotech.co.uk

MediBeacon

MediBeacon

Exhibition Partner

MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on developing actionable point of care organ function measurements. MediBeacon technology is being shown to have many preclinical nephrology applications with over 500 peer-reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used. In 2018 the U.S. Food and Drug Administration granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). Clinical studies in subjects with normal and impaired kidney function are ongoing. The Phase 3 TGFR Pivotal Study was completed in 2023.

www.medibeacon.com

 

almac

Almac

Exhibition Partner

Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories:
- Genomic Services (Range of Platforms & Technologies, Sample Management, Data Sciences)
- Clinical Trial Assays (Research Use Assays, Clinical Use Assays, Global Clinical Trial Testing)
- Companion Diagnostics (CDx Development, CDx Manufacture, CDx Commercialisation)

www.almacgroup.com

 

Perspectum_RGB_NoTM (1)

Perspectum

Exhibition Partner

Pioneering precision healthcare, Perspectum is leading innovation in non-invasive technology. The company’s track record speaks volumes, having delivered innovative imaging, operational excellence, and protocol consultation services in over 80 commercial trials spanning Phase 0-III in a range of chronic diseases. With a focus on kidney health, our quantitative MRI biomarker suite offers a comprehensive assessment of structural and functional metrics, enabling efficient patient screening and therapeutic efficacy assessment. Experience the future of kidney care with Perspectum's groundbreaking solutions.

www.perspectum.com

 

Alpine Logo Stacked

Alpine Immune Sciences

Industry Partner

A Unique Approach to Immunology

Alpine Immune Sciences (ALPN) is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Launched in 2015 and headquartered in Seattle, WA, we have created and advanced multiple product candidates into clinical trials for inflammatory/autoimmune diseases and cancer, formed collaborations with world-class partners, and built a robust development pipeline.

Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. Our lead candidate, povetacicept, is a dual BAFF/APRIL inhibitor injected once every four weeks. Povetacicept is currently in Phase Ib/IIa development for IgAN (IgA nephropathy), LN (lupus nephritis) and pMN (primary membranous nephropathy), in addition to other indications in hematology. For more information please visit our website:

www.alpineimmunesciences.com

chinook_logo (002)

Chinook Therapeutics, a Novartis company

Industry Partner

Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

www.novartis.com

ENYO Pharma_Logo_No background (002)

ENYO Pharma

Industry Partner

ENYO Pharma (Lyon, France) is a clinical-stage biopharmaceutical company. The company is developing a portfolio of drug candidates to improve quality of life and avoid end stage renal disease and dialysis for patients with rare and common kidney diseases. Its lead candidate Vonafexor, as well as fast follower EYP651, is a once-daily oral treatment.  Both compounds have fibrolytic and anti-inflammatory properties that are broadly applicable across several renal diseases. ENYO Pharma is currently starting its Phase 2 ALPESTRIA-1 study to confirm Vonafexor’s effect on renal function (eGFR) in Alport Syndrome, as was seen in its Phase 2 LIVIFY study of patients with both kidney impairment and fibrotic liver disease. ENYO Pharma is also preparing additional Phase 2 trials to extend its franchise to other renal diseases.

www.enyopharma.com

vera

Vera Therapeutics

Industry Partner

Vera Therapeutics is a latestage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868.

www.veratx.com

IgAN-fullcolor-logo

IgA Nephropathy Foundation

Hosting Partner

The IgA Nephropathy Foundation’s mission is to be a patient-centric organization focused on finding a cure for IgA Nephropathy. Using the power of the patient community, we are focused on funding research, using patient advocacy to empower our patients, and building a network of support.

As a patient-run organization, we will work together with the hope of finding better treatment options and, ultimately, a cure.

By patients, for patients.

www.igan.org

Logo Physiogenex

Physiogenex

Event Partner

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis.

For >20 years, we have been evaluating the efficacy of our clients' drugs using gold-standard experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.

Our expertise – your success.

www.physiogenex.com

2023_gubra_logo-blue

Gubra

Event Partner

Gubra provides a wide range of services within chronic kidney diseases (CKD) enabling fast, data-driven decisions moving preclinical targets and drug discovery projects forward. We maintain a constant focus on providing solid data as well as completing projects on time, within budget and to the highest scientific standards. Our services include preclinical studies in a wide selection of rodent models of CKD, including hypertension/metabolic induced diabetic kidney disease, surgically and toxin induced CKD as well as polycystic kidney disease. Studies can be combined with high-end capabilities within histology, advanced single cell RNA sequencing, spatial transcriptomics and whole-organ 3D imaging.

www.gubra.dk